Literature DB >> 11344047

Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture.

R M Pereira1, A M Delany, E Canalis.   

Abstract

Glucocorticoids decrease the replication of cells of the osteoblastic lineage and the function of the osteoblast. However, under certain conditions, they enhance the differentiation of osteoblastic cells, an effect that appears contradictory to their inhibitory actions on cell function. In this study we examine the effects of cortisol on the proliferation, differentiation, and fate of osteoblastic enriched cells from 22-day-old fetal rat calvariae (osteoblastic cells) in the absence and presence of beta-glycerophosphate. In the absence of beta-glycerophosphate, there was a progressive accumulation of DNA and cells, which was impaired by cortisol. In the presence of beta-glycerophosphate, there was an initial accumulation of DNA and cells followed by a marked decline that was prevented by cortisol. Despite the sustained number of cells, cortisol did not affect their mineralization, and inhibited Core binding factor a1 (Cbfa1), but not alkaline phosphatase, osteocalcin, or type I collagen transcripts. The decrease in cell number by cortisol observed in the absence of beta-glycerophosphate was due to a decrease in DNA synthesis, whereas the increase in cell number observed in the presence of beta-glycerophosphate was due to a relative increase in DNA synthesis and a decrease in apoptosis as determined by DNA fragmentation and acridine orange staining of the cells. This was correlated by a decrease in transcripts of proapoptotic genes and caspase 3 activity, and an increase of antiapoptotic genes. In conclusion, cortisol decreases the replication of cells of the osteoblastic lineage, but under conditions of differentiation/mineralization, cortisol prevents terminal differentiation of the cells and maintains an immature cell population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344047     DOI: 10.1016/s8756-3282(01)00422-7

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  30 in total

Review 1.  Mechanisms of glucocorticoid action in bone.

Authors:  Ernesto Canalis
Journal:  Curr Osteoporos Rep       Date:  2005-09       Impact factor: 5.096

2.  Socioeconomic status, race, and bone turnover in the Midlife in the US Study.

Authors:  C J Crandall; D Miller-Martinez; G A Greendale; N Binkley; T E Seeman; A S Karlamangla
Journal:  Osteoporos Int       Date:  2011-08-03       Impact factor: 4.507

3.  Glucocorticoids suppress bone formation via the osteoclast.

Authors:  Hyun-Ju Kim; Haibo Zhao; Hideki Kitaura; Sandip Bhattacharyya; Judson A Brewer; Louis J Muglia; F Patrick Ross; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

Review 4.  Minireview: nuclear receptor regulation of osteoclast and bone remodeling.

Authors:  Zixue Jin; Xiaoxiao Li; Yihong Wan
Journal:  Mol Endocrinol       Date:  2014-12-30

5.  Osteoblast Differentiation and Bone Matrix Formation In Vivo and In Vitro.

Authors:  Harry C Blair; Quitterie C Larrouture; Yanan Li; Hang Lin; Donna Beer-Stoltz; Li Liu; Rocky S Tuan; Lisa J Robinson; Paul H Schlesinger; Deborah J Nelson
Journal:  Tissue Eng Part B Rev       Date:  2016-12-27       Impact factor: 6.389

Review 6.  Pediatric Osteoporosis: Diagnosis and Treatment Considerations.

Authors:  Edoardo Marrani; Teresa Giani; Gabriele Simonini; Rolando Cimaz
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

7.  Effect of prednisone treatment for 30 and 90 days on bone metabolism in collagen-induced arthritis (CIA) rats.

Authors:  Xinle Zhang; Xuna Wu; Yalin Min; Jiaqi Lu; Xuemei Zhang; Wenshuang Chen; Liyi Zou; Xiaohua Lv; Liao Cui; Bilian Xu
Journal:  J Bone Miner Metab       Date:  2017-11-09       Impact factor: 2.626

Review 8.  Nuclear receptors in bone physiology and diseases.

Authors:  Yuuki Imai; Min-Young Youn; Kazuki Inoue; Ichiro Takada; Alexander Kouzmenko; Shigeaki Kato
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

9.  First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.

Authors:  Thomas Lund; Kent Søe; Niels Abildgaard; Patrick Garnero; Per T Pedersen; Tina Ormstrup; Jean-Marie Delaissé; Torben Plesner
Journal:  Eur J Haematol       Date:  2010-07-22       Impact factor: 2.997

Review 10.  Glucocorticoid-induced osteoporosis in rheumatic diseases.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ernesto Canalis
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.